Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.63M fell 18.9% year over year, ahead of the -47.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 13.2% from the prior quarter. Over 3 fiscal years it compounded at -30.3% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -18.9% holds above the trailing-twelve-month pace of -47.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.96M USD
- Year-over-year change
- -50.4%
- 4-year CAGR
- -22.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.96M | -50.4% |
| FY2024 | 2024-12-31 | 30.19M | -31.1% |
| FY2023 | 2023-12-31 | 43.81M | -0.9% |
| FY2022 | 2022-12-31 | 44.19M | +9.1% |
| FY2021 | 2021-12-31 | 40.49M | — |
Stock-Based Compensation vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 stock-based compensation of $13.93M is the 2nd largest of the 9 companies compared; the peer median is $11.02M.
- Its year-over-year change of -47.2% is the lowest of 9, against a peer median of -25.4%.
- Over three fiscal years its annual growth of -30.3% compares with a peer median of +5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $13.93M | -47.2% | -30.3% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $12.39M | -37.2% | -5.9% | — | |
| LTM Mar 2026 | $11.29M | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Mar 2026 | $7.34M | -25.5% | -15.1% | 2.9% | |
CBUSCibus, Inc. | LTM Mar 2026 | $7.26M | -32.3% | +27.0% | 169.4% |
| LTM Mar 2026 | $5.81M | -25.3% | -16.6% | — | |
| Peer median (excluding RLMD) | $11.02M | -25.4% | +5.8% | 75.8% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Depreciation & Amortization | 1.26K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.49M | 44.19M | 43.81M | 30.19M | 14.96M |
| Change in Working Capital | (7.86M) | 10.59M | 3.08M | (1.58M) | (3.95M) |
| Accounts Receivables | 79.46K | (426.06K) | 512.43K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.85M | 421.04K | (1.76M) | 624.55K | (2.56M) |
| Other Working Capital | (10.79M) | 10.6M | 4.32M | (2.21M) | (1.39M) |
| Other Non-Cash Items | 1.25M | (1.55M) | 241.16K | (381.66K) | 586.18K |
| Operating Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
| Capital Expenditures | 0 | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (222.98M) | (47.29M) | (90.46M) | (12.08M) | (83.83M) |
| Sales of Investments | 168.86M | 67.03M | 140.92M | 63.64M | 35.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.12M) | 19.73M | 50.45M | 51.56M | (48.14M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 185.31M | 42.73M | 0 | 246.75K | 93.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.63M | 2.29M | (98.46K) | (287.09K) | (73.02K) |
| Financing Cash Flow | 187.94M | 45.02M | (98.46K) | (40.34K) | 93.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.95M | (39.05M) | (1.3M) | (234.54K) | (360.49K) |
| Free Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.